絞り込み

17048

広告

Safety and efficacy of nivolumab in challenging subgroups with advanced melanoma who progressed on or after ipilimumab treatment: A single-arm, open-label, phase II study (CheckMate 172).

著者 Schadendorf D , Ascierto PA , Haanen J , Espinosa E , Demidov L , Garbe C , Guida M , Lorigan P , Chiarion-Sileni V , Gogas H , Maio M , Fierro MT , Hoeller C , Terheyden P , Gutzmer R , Guren TK , Bafaloukos D , Rutkowski P , Plummer R , Waterston A , Ka
Eur J Cancer.2019 Sep 30 ; 121():144-153.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (10view , 0users)

Full Text Sources

Medical

Limited data are available on nivolumab in challenging subgroups with advanced melanoma. We report outcomes of nivolumab after prior ipilimumab in patients who are typically excluded from clinical trials.
PMID: 31581055 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード